Gyre Therapeutics (GYRE) Depreciation & Amortization (CF) (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Depreciation & Amortization (CF) of $672000.0 for Q1 2026, up 25.61% year-over-year from $535000.0 in Q1 2025, and up 2.44% quarter-over-quarter from $656000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $672000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 25.61% year-over-year to $672000.0; the TTM figure through Mar 2026 stood at $2.6 million (up 56.86% YoY), while the FY2025 annual figure was $2.5 million, up 60.17% from the prior year.
- Depreciation & Amortization (CF) climbed to $672000.0 in Q1 2026 per GYRE's latest filing, from $656000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $867000.0 in Q4 2022 and bottomed at $40000.0 in Q3 2022.
- Historically, Depreciation & Amortization (CF) has averaged $403705.9 across 5 years, with a median of $415000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 653.91% — and 2023, when it tumbled 65.63%.
- Gyre Therapeutics' Depreciation & Amortization (CF) stood at $867000.0 in 2022, then sank by 65.63% to $298000.0 in 2023, then soared by 54.7% to $461000.0 in 2024, then jumped by 42.3% to $656000.0 in 2025, then increased by 2.44% to $672000.0 in 2026.
- Business Quant data shows GYRE's Depreciation & Amortization (CF) at $672000.0 in Q1 2026, $656000.0 in Q4 2025, and $649000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | 1.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.48 Mn |
| Mar 31, 2026 | 672,000.00 |
| Dec 31, 2025 | 656,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 535,000.00 |
| Dec 31, 2024 | 461,000.00 |
| Sep 30, 2024 | 445,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 415,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Jun 30, 2023 | 308,000.00 |
| Mar 31, 2023 | 276,000.00 |
| Dec 31, 2022 | 867,000.00 |
| Sep 30, 2022 | 40,000.00 |
| Jun 30, 2022 | 67,000.00 |
| Mar 31, 2022 | 113,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Sep 30, 2021 | 85,000.00 |